Marshall Edwards, Inc. Appoints Professor Bryan Williams as Chairman
November 28 2006 - 8:27AM
PR Newswire (US)
WASHINGTON, Nov. 28 /PRNewswire-FirstCall/ -- The Board of
Directors of Marshall Edwards, Inc. (NASDAQ:MSHL) has appointed
Professor Bryan Williams as the non-executive chairman. Professor
Williams is the Director of the Monash Institute of Medical
Research (MIMR), in Melbourne, Australia and also heads the Centre
for Cancer Research at MIMR. He joined the board of Marshall
Edwards, Inc. as a non- executive director in March 2006. He was
previously the Chairman of the Department of Cancer Biology at the
Lerner Research Institute of the Cleveland Clinic Foundation in
Cleveland, Ohio, USA. He was also an Associate Director of the Case
Comprehensive Cancer Center in Cleveland. Professor Williams has a
distinguished career in cancer research. In addition to his work in
the U.S. and Australia, he has previously worked in Canada, England
and New Zealand, specializing in the molecular biology of tumor
suppression, and focusing on the role tumor suppressor genes may
play in regulating cell growth, maturation and apoptosis
(programmed cell death). He is internationally recognized for his
contributions to research on Wilms Tumor, a cancer of the kidney
that primarily affects children, for studies on protein kinase R,
an important cellular signaling molecule and for work on innate
immunity. Professor Williams said, "It is a privilege to chair the
company at this very exciting time in its clinical and commercial
development." "We have just announced the treatment of the first
patient in the pivotal phase III 'Ovature' ovarian cancer
multi-national clinical trial, and over the next year will be
treating patients in this clinical trial in the U.S., Europe and
Australia," he said. He added that the Company has also appointed
J.P. Morgan as its exclusive financial advisors to assist in its
strategic development and to coordinate the commercialization
opportunities for the drug candidate phenoxodiol. Professor
Williams succeeds Dr. Graham Kelly who remains a non-executive
director of the Company. About Marshall Edwards, Inc. Marshall
Edwards, Inc. (NASDAQ:MSHL) has licensed rights from Novogen
Limited (NASDAQ:NVGN) to bring three oncology drugs -- phenoxodiol,
NV-196 and NV-143 -- to market globally. Marshall Edwards, Inc. is
majority owned by Novogen, an Australian biotechnology company that
is specializing in the development of therapeutics based on a
flavonoid technology platform. Novogen, based in Sydney, Australia,
is developing a range of therapeutics across the fields of
oncology, cardiovascular disease and inflammatory diseases. More
information on phenoxodiol and on the Novogen group of companies
can be found at http://www.marshalledwardsinc.com/ and
http://www.novogen.com/. Under U.S. law, a new drug cannot be
marketed until it has been investigated in clinical trials and
approved by the FDA as being safe and effective for the intended
use. Statements included in this press release that are not
historical in nature are "forward-looking statements" within the
meaning of the "safe harbor" provisions of the Private Securities
Litigation Reform Act of 1995. You should be aware that our actual
results could differ materially from those contained in the
forward-looking statements, which are based on management's current
expectations and are subject to a number of risks and
uncertainties, including, but not limited to, our failure to
successfully commercialize our product candidates; costs and delays
in the development and/or FDA approval, or the failure to obtain
such approval, of our product candidates; uncertainties in clinical
trial results; our inability to maintain or enter into, and the
risks resulting from our dependence upon, collaboration or
contractual arrangements necessary for the development,
manufacture, commercialization, marketing, sales and distribution
of any products; competitive factors; our inability to protect our
patents or proprietary rights and obtain necessary rights to third
party patents and intellectual property to operate our business;
our inability to operate our business without infringing the
patents and proprietary rights of others; general economic
conditions; the failure of any products to gain market acceptance;
our inability to obtain any additional required financing;
technological changes; government regulation; changes in industry
practice; and one-time events. We do not intend to update any of
these factors or to publicly announce the results of any revisions
to these forward-looking statements. DATASOURCE: Marshall Edwards,
Inc. CONTACT: Christopher Naughton, CEO of Marshall Edwards, Inc.,
+612 8877 6196; or David Sheon of SciWords, LLC, +1-202-518-6321,
for Marshall Edwards, Inc. Web site:
http://www.marshalledwardsinc.com/ http://www.novogen.com/
Copyright
Kazia Therapeutics (NASDAQ:KZIA)
Historical Stock Chart
From Jun 2024 to Jul 2024
Kazia Therapeutics (NASDAQ:KZIA)
Historical Stock Chart
From Jul 2023 to Jul 2024